Why Immunomedics Inc. Shares Popped

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Immunomedics (NASDAQ: IMMU  ) , a clinical-stage developer of monoclonal antibodies to help treat cancer and autoimmune disorders, rose as much as 12% after announcing the receipt of a U.S. patent for its antibody-SN-38 conjugates.

So what: Immunomedics' patent covers its linking technology (the aforementioned antibody-drug conjugate) that allows a chemotherapy toxin to be piggybacked on an antibody and delivered directly to a targeted cancer cell where it's released when it comes into contact with that cancer cell. Currently, Immunomedics has two ADC's in development, IMMU-132 and IMMU-130, which are both in mid-stage clinical trials. Data from these trials is expected by the second-quarter. Immunomedics also announced a new patent with "additional claims for the labeling of peptides and protein, including antibodies that utilize F-18.

Now what: It's not too late to score one more win for Immunomedics in 2013! This patent issuance is important as it protects the company's proprietary ADC platform from competitors and could set up Immunomedics for a flurry of partnerships if these upcoming mid-stage trials prove successful. This is certainly an exciting name you'll want to keep an eye on in 2014.

Here's the other stock you should be watching in 2014!
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2780218, ~/Articles/ArticleHandler.aspx, 9/29/2016 1:28:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,170.95 -168.29 -0.92%
S&P 500 2,153.91 -17.46 -0.80%
NASD 5,270.14 -48.41 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 1:09 PM
IMMU $3.25 Down -0.15 -4.28%
Immunomedics CAPS Rating: *****